ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

encequidar

Also written as “HM30181AK tablet + Irinotecan tablets”, “Oral Paclitaxel in combination with Encequidar tablet” and “Encequidar tablet”.

Its studies are mostly in Breast Neoplasms, led by 2 companies.

Drug pageHm-30181: every studyAll 6 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Aug 6, 20096 company-led studies, 2 open or runningNext primary completion: Dec 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Hanmi Pharmaceutical40 open or runningphase 1since Aug 6, 2009Aug 6, 2009none ahead
Health Hope Pharmaits history only22 open or runningphase 3since Feb 14, 2025Feb 14, 2025Dec 2026phase 1 · NCT07580833

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Hanmi Pharmaceutical only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

  1. Aug 6, 2009First study: phase 1 study in HealthyFirst studyNCT00954304 · 30 enrolled · Korea, Republic of
  2. Sep 16, 20092 phase 1 studies in Advanced Solid MalignanciesNCT00979563, NCT00986843
  3. Dec 5, 2011Phase 1 study in Advanced Solid TumorsNCT01491204 · 25 enrolled
  4. Jun 9, 2018Named encequidarINNProposed as its International Nonproprietary Name in WHO's List 119

TargetBeta

ABCB1 →read by rule
“P-glycoprotein 1 inhibitor”ChEMBL 37, by rule

Studies

All 4 Hanmi Pharmaceutical leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01491204Advanced Solid Tumors1CompletedOct 200825
NCT00986843Advanced Solid Malignancies · Korea, Republic of1CompletedFeb 201014
NCT00979563Advanced Solid Malignancies · Korea, Republic of1CompletedMar 201015
NCT00954304Healthy · Korea, Republic of1CompletedAug 200930

How it is read

Names in the registry

  • “HM30181AK tablet + Irinotecan tablets”, 2 entries
  • “Oral Paclitaxel in combination with Encequidar tablet”, 1 entry
  • “Encequidar tablet”, 1 entry
  • “Paclitaxel+HM30181”, 1 entry
  • “HM30181AK 1mg”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.